OC-1 cells are a type of treatment used in this clinical trial for patients with a specific kind of blood cancer called T-cell acute lymphoblastic leukemia or lymphoma. These cells are a form of CAR-T cell therapy, which means they are specially modified cells that are designed to find and attack cancer cells in the body. The goal of using OC-1 cells is to help the immune system target and destroy the cancer cells more effectively. In this trial, patients who have already received OC-1 cells are being monitored over a long period to check for any delayed side effects and to see how well the treatment works over time.

T-cell Acute Lymphoblastic Leukemia – T-cell Acute Lymphoblastic Leukemia is a type of cancer that affects the blood and bone marrow, characterized by the overproduction of immature white blood cells known as lymphoblasts. These abnormal cells crowd out normal cells, leading to a decrease in healthy blood cells. The disease progresses rapidly, with symptoms such as fatigue, fever, and easy bruising or bleeding due to the lack of normal blood cells. As the disease advances, it can spread to other parts of the body, including the lymph nodes, liver, and spleen. The accumulation of lymphoblasts can also cause bone pain and swelling in the lymph nodes.

T-cell Acute Lymphoblastic Lymphoma – T-cell Acute Lymphoblastic Lymphoma is a type of non-Hodgkin lymphoma that originates from T-cells, a type of white blood cell. It is characterized by the rapid growth of malignant lymphocytes, which can form tumors in lymphoid tissues such as the lymph nodes, thymus, and spleen. The disease progresses quickly, often presenting with symptoms like swollen lymph nodes, chest pain, and difficulty breathing due to the enlargement of the thymus. As it advances, it can spread to other organs and tissues, including the bone marrow and central nervous system. The accumulation of cancerous cells can lead to systemic symptoms such as fever, night sweats, and weight loss.